Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 46
- Registration Number
- NCT01129557
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-05-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01115972
FOCUS (Nifedipine GITS's Effect on Central Pressure Assessed by Applanation Tonometry)
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 365
- Registration Number
- NCT01071122
To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
- Conditions
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT01070043
Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 121
- Registration Number
- NCT00982358
- Locations
- 🇩🇪
University of Ulm, Department of Internal Medicine II, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Charité University Medicine Berlin, Center for Cardiovascular Research, Outpatient Clinic, Berlin, Germany
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1143
- Registration Number
- NCT00927394
- Locations
- 🇺🇸
Investigative Site, Philadelphia, Pennsylvania, United States
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 105
- Registration Number
- NCT00921570
- Locations
- 🇹🇷
GATA Nephrology, Ankara, Turkey
Valsartan Intensified Primary Care Reduction of Blood Pressure Study
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2012-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2337
- Registration Number
- NCT00902304
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
🇦🇺Professor Simon Stewart-Principal Investigator, Melbourne, Australia
🇦🇺Professor Garry Jennings-Co Principal Investigator, Melbourne, Australia
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 307
- Registration Number
- NCT00887588
- Locations
- 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela
The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 500
- Registration Number
- NCT00858299
- Locations
- 🇰🇷
Division of Nephrology, Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.